ICR gene signature to identify differential immune landscapes in anatomic subsites of head and neck squamous cell carcinomas and implications in personalized medicine
6052Background: Head and neck squamous cell carcinoma (HNSCC) patients have a 16-25% response rate to single agent immune checkpoint inhibitors (ICI). Prognostic biomarkers to ICIs are needed to id...